GlassScriptPhysician profile
Abby Lynn Buchman
NPI 1700514049
$3,057.29
in general payments reported to CMS, 2019-2025
22 companies · $1,683 in 2025
The $1,683 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $53.52 · 2023: $934 · 2024: $387 · 2025: $1,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,174 · Travel and Lodging: $805 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,173.86 |
| Travel and Lodging | $804.91 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fortis Surgical, LLC | $918.01 | 2025 | |
| Arthrex, INC. | $550.90 | 2025 | |
| Abbvie INC. | $225.29 | 2022-2024 | |
| Depuy Synthes Sales INC. | $206.26 | 2024-2025 | Motoband, Minibunion, Peak |
| Glaxosmithkline, LLC. | $163.26 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $158.47 | 2023-2024 | Farxiga, Breztri, Airsupra |
| Bioventus LLC | $129.42 | 2024-2025 | Exogen Ultrasound Bone Healing System |
| Novo Nordisk INC | $126.14 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $121.43 | 2023-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $71.46 | 2023 | Xarelto |
| Corcept Therapeutics | $60.17 | 2023-2024 | Korlym |
| Fidia Pharma USA INC. | $58.53 | 2023 | Triluron |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.45 | 2022-2024 | Jardiance |
| Currax Pharmaceuticals LLC | $38.38 | 2023 | Nexletol, Contrave |
| Insulet Corporation | $36.49 | 2023 | Omnipod |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $28.14 | 2023 | Zilretta, Iovera |
| Pfizer INC. | $26.15 | 2023 | |
| Sanofi Pasteur INC. | $25.81 | 2023 | |
| Dexcom, INC. | $18.32 | 2023 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $16.92 | 2024 | Jardiance, Zepbound |
| Teva Pharmaceuticals USA, INC. | $16.37 | 2022 | |
| Dynasplint Systems INC. | $14.92 | 2025 | Dynasplint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abby Buchman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.